Characteristic | Â | No. (%) of patients | Drug-resistant vs. Pan-sensitive OR (95Â % CI) | MDR vs. Pan-sensitive OR (95Â % CI) | ||||
---|---|---|---|---|---|---|---|---|
Total (n = 1427) | Pan-sensitive (n = 613) | Drug-resistant (n = 489) | MDR (n = 325) | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |
Sex | ||||||||
 Male | 994(69.7) | 425 (69.3) | 343(70.1) | 226 (69.5) | Referent | NA | Referent | NA |
 Female | 433(30.3) | 188 (30.7) | 146(29.9) | 99 (30.5) | 1.0 (0.8–1.3) | NA | 1.0 (0.7–1.4) | NA |
Age group, y | ||||||||
 7–34 | 469(32.9) | 234(38.2) | 152(31.1) | 83 (25.5) | Referent | Referent | Referent | Referent |
 35–54 | 587(41.1) | 198 (32.3) | 215(44.0) | 174 (53.5) | 1.7 (1.3–2.2) | 1.5 (1.1–2.0) | 2.5 (1. 8–3.4) | 1.7 (1.2–2.5) |
  ≥ 55 | 371(26.0) | 181 (29.5) | 122(24.9) | 68 (20.9) | 1.0 (0.8–1.4) | 0.9 (0.7–1.2) | 1.0 (0.7, 1.5) | 0.6 (0.4–0.9) |
History of TB treatment | ||||||||
 No | 918(64.1) | 471 (76.8) | 322(65.8) | 125 (38.5) | Referent | Referent | Referent | Reference |
 Yes | 509(35.7) | 142(23.2) | 167(34.2) | 200 (61.5) | 1.7 (1.3–2.2) | 1.7 (1.2–2.1) | 5.3 (4.0–7.1) | 3.6 (2.6–5.0) |
Cavity visible on radiographb | ||||||||
 No | 442(35.2) | 222 (39.8) | 147(34.9) | 73 (26.5) | Referent | Referent | Referent | Referent |
 Yes | 812(64.8) | 336 (60.2) | 274(65.1) | 202 (73.5) | 1.2 (0.9–1.6) | 1.2 (0.9–1.6) | 1.8 (1.3–2.5) | 1.6 (1.0–2.2) |
With standard hospitalization | ||||||||
 Yes | 1021(71.5) | 496 (80.9) | 396 (81.0) | 129 (39.7) | Referent | NA | Referent | Referent |
 Noc | 406(28.5) | 117 (19.1) | 93(19.0) | 196 (60.3) | 1.0 (0.7–1.3) | NA | 6.4 (4.8–8.7) | 5.0 (3.6–7.0) |
Beijing genotyped | ||||||||
 No | 31(10.3) | 17 (14.8) | 11 (10.2) | 3 (3.9) | Referent | NA | Referent | NA |
 Yes | 269(89.7) | 98 (85.2) | 97 (89.8) | 74 (96.1) | 1.5 (0.7–3.4) | NA | 4.3 (1.2–15.1) | NA |